Literature DB >> 11245475

Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection.

T Liloglou1, P Maloney, G Xinarianos, M Hulbert, M J Walshaw, J R Gosney, L Turnbull, J K Field.   

Abstract

We examined genomic instability in DNA from 80 bronchial lavage samples from patients with lung cancer and individuals with no malignant lung disease. We used a multiplex assay of eight fluorescent-tagged microsatellite markers that have a very high incidence of allelic imbalance in lung tumors. When genomic instability at individual loci was analyzed statistically against diagnosis, markers D3S1289 (P = 0.033), D3S1300 (P = 0.001), D13S171 (P = 0.009), and D17S2179E (P = 0.017) demonstrated significantly higher frequency of instability in bronchial lavage specimens from lung cancer cases than those with nonmalignant conditions. In contrast, markers D9S157, D9S161, D13S153, and D5S644 demonstrated lower specificity (P > 0.05) for lung tumors. These results suggest that genomic instability in some loci may be related to high proliferation rates but not necessarily to cell commitment to malignancy. When genomic instability was scored with only the four cancer-specific markers, the assay produced a sensitivity of 73.9% and a specificity of 76.5%. On combining the results from the cytological examination and the molecular assay, the sensitivity reached 82.6%. These results indicate that in our efforts to investigate genomic instability as a potential marker for the early detection of lung cancer, we need to identify cancer-specific genomic instability markers. This paper has shown that these first four markers may be considered to form an individual set of cancer-specific genomic instability markers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245475

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination.

Authors:  Andrew G Schache; Triantafilos Liloglou; Janet M Risk; Anastasia Filia; Terence M Jones; Jon Sheard; Julia A Woolgar; Timothy R Helliwell; Asterios Triantafyllou; Max Robinson; Philip Sloan; Colin Harvey-Woodworth; Daniel Sisson; Richard J Shaw
Journal:  Clin Cancer Res       Date:  2011-10-01       Impact factor: 12.531

2.  MiR-144-3p inhibits the proliferation and metastasis of lung cancer A549 cells via targeting HGF.

Authors:  Guiju Fang; Canhui Zhang; Zhixin Liu; Zhiwen Peng; Meiyan Tang; Qing Xue
Journal:  J Cardiothorac Surg       Date:  2022-05-14       Impact factor: 1.522

3.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

4.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Authors:  Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

5.  Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP.

Authors:  Duan Mengxi; Wang Qian; Wang Nan; Xiao Xiaoguang; Li Shijun
Journal:  Cancer Cell Int       Date:  2013-09-08       Impact factor: 5.722

6.  DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer.

Authors:  Georgios Nikolaidis; Olaide Y Raji; Soultana Markopoulou; John R Gosney; Julie Bryan; Chris Warburton; Martin Walshaw; John Sheard; John K Field; Triantafillos Liloglou
Journal:  Cancer Res       Date:  2012-09-07       Impact factor: 12.701

7.  Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability.

Authors:  S L Smith; N L Bowers; D C Betticher; O Gautschi; D Ratschiller; P R Hoban; R Booton; M F Santibáñez-Koref; J Heighway
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.